You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Southeast Xlerator Network
SBC: XLERATEHEALTH, LLC Topic: RThe Southeast XLerator Network proposes to create a networked and easily accessible regional technology transfer accelerator hub (“XLerator Hub” or “Hub”) to share best practices, disseminate education content, and offer products, services, facilities and other resources connected through both physical and online platforms for innovators and trainees in the Southeast IDeA states. Led by XL ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Enabling point-of-care molecular diagnostics by developing an adaptive PCR instrument and on-demand kit reagents
SBC: BIOVENTURES, INC Topic: 172Because of its high sensitivitypolymerase chain reactionPCRis the gold standard for the diagnosis of many infectious diseasesbut generally only implemented in well equipped laboratoriesOne of the major roadblocks for expanding PCR to point of care markets is the lack of simplerobustsingle tube PCR designs which preserve its laboratory based high sensitivity and specificityIn this Fast Track STTR a ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Validation of a salivary miRNA diagnostic test for autism spectrum disorder
SBC: Quadrant Biosciences Inc. Topic: 103Autism spectrum disorder (ASD) is a continuum of neurodevelopmental characteristics that includes deficits in communication and social interaction, as well as restrictive, repetitive interests and behaviors. ASD is an increasing public health concern, with about 1 in 45 American children diagnosed with ASD in 2014, a 10-fold increase in prevalence over the past 40 years. The effect of ASD on both ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Developing a Small Peptide to Control Autoimmune Inflammation In Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIAIDType 1 Diabetes (T1D) affects an ever growing population. While this disease typically has been associated with juveniles, the disease in adult populations is rapidly increasing. The defining clinical component is insulin loss, which occurs because of sustained inflammation in the islets. At present there is no means to prevent or reverse insulin loss. A major inflammatory pathway in T1D that cont ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Jamboxx: Interactive Respiratory Therapy through Music and Gaming
SBC: My Music Machines Inc. Topic: NHLBIProject SummaryAbstract The goal of this project is to develop a novel device for respiratory therapy that uses interactive gaming and music to encourage patient complianceIn order to maintain pulmonary healthmany post operative surgery patients as well as people with quadriplegia and other spinal cord injurieshigh level motor neuron diseases such as amyotrophic lateral sclerosisALSand multiple sc ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Oxidation-resistant Anti-protease Therapy
SBC: LEXEO Therapeutics LLC Topic: NHLBIAbstract. LEXEO Therapeutics, LLC, is an early stage biotechnology company focused on using gene therapy technologies to protect vulnerable organs from oxidant stress. LEX01, the 1st LEXEO product, is a 1st in class, next generation gene therapy treatment for alpha 1-antitrypsin (AAT) deficiency, an autosomal recessive hereditary disorder associated with low serum levels of AAT. AAT (SERPINA1), a ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Electronic Optimization of Stem Cell Derived Human Cardiac Myocytes
SBC: Cytocybernetics Inc Topic: NHLBIProject Summary As part of the FDA approval process for novel therapeutic drugssafety screening demonstrating that the candidate drug does not have deleterious effects on the human cardiac action potential is requiredHealthy human heart cells are not available for such preclinical drug testingThere is currently no consensus on the best experimental approach to provide the most efficienteconomicala ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health -
Improvements to Biopharmaceutical Manufacturing
SBC: HocusLocus Inc. Topic: 400PROJECT SUMMARY Over $billion dollarsworth of biological productsincluding antibodiesvaccines and proteinsare produced each yearThis continues to grow worldwide at aboutyearmaking biopharmaceuticals a fairly recession proofgrowing and pro table industryThis shift towards biopharmaceuticals re ects a fundamental shift within the pharmaceutical industryBiomanufacturers are under constant pressure to ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Scientific Merit and Feasibility of Fructokinase Inhibition for Obesity
SBC: COLORADO RESEARCH PARTNERS LLC Topic: 300Our goal is to develop a firstin class therapeutic agent that directly blocks the metabolism of fructosea key component in sugarIntake of sugarsucroseand high fructose corn syrupHFCSinduces metabolic syndrome and diabetes in laboratory animals and are strongly associated with obesity and diabetes in humansBoth sucrose and HFCS contain fructosewhich stimulates food intake by inducing leptin resista ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Development of a Clinical Screening Platform for Type 1 Diabetes
SBC: Op-T-Mune, Inc Topic: NIDDKAbstractA major shortfall in clinical care for diabetes is a rapid and accurate screen for progression to diseaseCurrent criteria involve HLA haplotypeand the presence of auto antibodiesAAGenome wide associated studiesGWASrevealed only immune associated genes including HLA as T D predictorsThe ability to differentiate from other diseases was very limitedPre typediabetesp T Dis now being identified ...
STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health